Sponsors (5)
The bill speeds and simplifies patient access to lower-cost biosimilars and reduces regulatory burden for manufacturers, but it trades off potential patient safety and pediatric evidence gaps, reduced incentives to generate switching data, less labeling transparency, and short-term market uncertainty.
Patients who use biologic therapies (especially those with chronic conditions) will more quickly gain access to lower-cost biosimilars because all 351(k) biosimilars are automatically deemed interchangeable, simplifying pharmacy substitution.
Biosimilar manufacturers (including small businesses) face a single licensure pathway instead of a separate interchangeability application, lowering regulatory burden and potentially reducing development costs.
Hospitals, health systems, and applicants will get clearer regulatory expectations because HHS/FDA must update guidances within 18 months, improving predictability for implementation and submissions.
Patients using biologics (particularly chronic patients) could face safety or efficacy risks from automatic deemed interchangeability if switching between products carries individual clinical risks.
Clinicians, hospitals, and payers may have less robust switching evidence because manufacturers will have reduced incentives to generate specific interchangeability data or studies.
Narrowing labeling and product-description requirements could limit information available to clinicians and patients about switching criteria or product differences, reducing transparency for treatment decisions.
Based on analysis of 2 sections of legislative text.
Removes the separate interchangeability application and deems 351(k) biosimilars automatically interchangeable after a 60‑day transition, with preserved existing exclusivities and revised application rules.
Introduced June 4, 2025 by Mike Lee · Last progress June 4, 2025
Changes the FDA pathway for biosimilars by removing a separate interchangeability application and making biosimilars licensed under the PHSA 351(k) pathway automatically "deemed interchangeable" under a 60‑day transition rule. It preserves any existing unexpired exclusivity for products already licensed as interchangeable, narrows certain application and labeling requirements, adjusts pediatric study triggers so most biosimilars are not treated as new active ingredients, and requires the FDA to update related guidances within set timeframes.